Expanded Access for Treatment With Imetelstat
Expanded Access Treatment With Imetelstat For Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Are Transfusion-Dependent And Have Failed to Respond or Have Lost Response or Are Ineligible For Erythropoiesis-Stimulating Agents (ESAs)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Expanded Access Type
Expanded Access Type
- Individual Patients: Allows a single patient, with a serious disease or condition who cannot participate in a clinical trial, access to a drug or biological product that has not been approved by the FDA. This category also includes access in an emergency situation.
- Intermediate-size Population: Allows more than one patient (but generally fewer patients than through a Treatment IND/Protocol) access to a drug or biological product that has not been approved by the FDA. This type of expanded access is used when multiple patients with the same disease or condition seek access to a specific drug or biological product that has not been approved by the FDA.
- Treatment IND/Protocol: Allows a large, widespread population access to a drug or biological product that has not been approved by the FDA. This type of expanded access can only be provided if the product is already being developed for marketing for the same use as the expanded access use.
- Intermediate-size Population
Contacts and Locations
Study Contact
Study Contact
- Name: WEP Clinical
- Phone Number: 919-694-5088
- Email: GeronEAP@wepclinical.com
Study Contact Backup
- Name: Shyamala Navada, MD
- Phone Number: 650-980-4256
- Email: mdseap-info@geron.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Documented diagnosis of MDS according to World Health Organization (WHO) criteria confirmed by bone marrow aspirate and/or biopsy preferably within 24 but no more than 52 weeks prior to EAP start.
- Very Low, Low, or Intermediate risk MDS (≤3.5) per IPSS-R.
- Red blood cell (RBC) transfusion dependent, defined as requiring at least 4 RBC units over an 8-week period during the 16 weeks prior to EAP entry; pre-transfusion hemoglobin (Hb) should be less than or equal to 9.0 grams per deciliter (g/dL) to count towards the 4 units total.
- Has MDS that has failed to respond or has lost response or are ineligible for ESAs.
- To ensure participants have adequate iron stores they must have transferrin saturation greater than 20% and serum ferritin greater than 400 nanograms per milliliter (ng/mL).
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
- Hematology and biochemical laboratory test values within the protocol defined limits.
- Have no approved alternative treatment available.
- Inability to participate in a current imetelstat clinical study for the disease or conditions.
- Have a treating physician who has appropriately evaluated the benefit/risk profile for potential imetelstat treatment.
Key Exclusion Criteria:
- Have previously assessed as having IPSS-R high or very high risk MDS.
- Participant with del(5q) karyotype.
- Participant with MDS/myeloproliferative neoplasm Overlap Syndromes.
- Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients.
- Participant has received an experimental or investigational product or used an invasive investigational medical device within 30 days prior to EAP entry or is currently enrolled in an investigational study.
- Prior treatment with imetelstat; or eligible for enrollment in an ongoing imetelstat clinical trial.
- Prior treatment with lenalidomide or a hypomethylating agent (example, azacitidine, decitabine, or decitabine/cedazuridine).
- Has received an ESA or any anti-MDS therapy, chemotherapy, immunomodulatory, or immunosuppressive therapy within 4 weeks prior to EAP entry.
- Prior history of hematopoietic stem cell transplant.
Note: Other protocol specified inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MDSEAP001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.